Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE)
preprint
OA: closed
Abstract
ABSTRACT Introduction Returning research results that indicate risk of Alzheimer disease (AD) - a disease for which no meaningful treatments or cure exist - to cognitively normal participants is controversial. AD is thought to begin many years before clinical signs and symptoms begin. During this time, individuals are cognitively normal, but have biomarkers that indicate pathophysiological changes in the brain. With this study, we aim to evaluate impact of returning research results on cognitively normal participants recruited from a longitudinal observational cohort on aging at the Knight Alzheimer Disease Research Center (Knight ADRC) at Washington University in St. Louis. Methods and analysis Our study uses a 2-year, delayed-start randomized clinical trial design. Participants are randomized to receive their research results either in 2-4 weeks or 1 year after informed consent. We plan to approach approximately 260 participants who have research results from previous genetic and biomarker testing at the Knight ADRC. The primary cognitive outcomes are 1-year change in subjective cognitive score (Clinical Dementia Rating (CDR ® ) sum of boxes), objective cognitive score (psychometric composite score), and the primary psychosocial outcome is Impact of Event-Revised score 1 year after return of research results. Ethics and dissemination This study has been approved by the WUSM Institutional Review Board (IRB) and the Human Research Protection Office (HRPO). Results from these trials are shared through conferences and publications. Trial registration number NCT04699786. Strengths and limitations of this study This study empirically evaluates how returning research AD biomarkers impacts participants both psychologically and cognitively using a randomized delayed-start clinical trial Multiple research AD biomarkers are synthesized into a single estimate for AD dementia risk A delayed-start design is necessary because it is unethical to withhold research results from participants but may limit the generalizability of the results because all participants will be receiving their research results
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00